摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮 | 21038-66-4

中文名称
吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮
中文别名
吡啶并[2,3-D]嘧啶-2,4-二醇
英文名称
1H-Pyrido[2,3-d]pyrimidine-2,4-dione
英文别名
pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione;1,2,3,4-tetrahydro-2,4-dioxo-pyrido<2,3-d>pyrimidine;Pyrido<2,3-d>pyrimidin-2,4(1H,3H)-dion;1,2,3,4-Tetrahydro-2,4-diazo-pyrido<2.3-d>pyrimidin;2,4-Dioxo-pyrido<2,3-d>pyrimidin
吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮化学式
CAS
21038-66-4
化学式
C7H5N3O2
mdl
MFCD07644628
分子量
163.136
InChiKey
JQPYINKVAWEQDQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    361℃
  • 密度:
    1.424

计算性质

  • 辛醇/水分配系数(LogP):
    -0.3
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    71.1
  • 氢给体数:
    2
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:8594304161a25dd6f9d9e8c74d7dd636
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 2,4-Dihydroxypyrido[2,3-d]pyrimidine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 2,4-Dihydroxypyrido[2,3-d]pyrimidine
CAS number: 21038-66-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5N3O2
Molecular weight: 163.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    杂芳基二酰胺和杂芳基二胺作为细胞毒性剂、凋亡诱导剂和 Caspase-3 激活剂的合成和生物学评价
    摘要:
    这里描述的工作涉及新的杂芳基二酰胺和杂芳基二胺的合成和生物学评价。本研究采用了一种可以调整结构的新通用模型。可以区分三个不同的结构单元:一个中央核和两个对称的终端单元。中心元素是不同长度和柔韧性的脂肪链、哌嗪或多胺核。然而,末端单元是具有不同取代基的吡啶、喹啉、吲哚、苯或吡啶并[2,3-d]嘧啶。通过检查它们对人乳腺癌、结肠癌和膀胱癌细胞系的细胞毒性作用,在体外评估了这些化合物的抗肿瘤活性。对显示出细胞毒性活性的化合物进行细胞凋亡和 caspase-3 检测。关于选择性,在两种非肿瘤细胞系的细胞培养物中也测定了细胞毒性。最有希望的化合物是 4c、5c 和 7,它们分别是氨基-吡啶鎓、喹啉-N-氧化物和吡啶基衍生物,这些化合物在测试的三种细胞系中的至少两种细胞系中显示出显着的体外细胞毒性。这些化合物诱导细胞凋亡,并且还导致 HT-29 细胞中 caspase-3 水平的快速剂量依赖性增加。还发现了其他令人鼓舞的特征,例如
    DOI:
    10.1002/ardp.200500220
  • 作为产物:
    参考文献:
    名称:
    Studies on Condensed Pyrimidine Systems. XII. Synthesis of Some 4- and 2,4-Substituted Pyrido[2,3-d]pyrimidines
    摘要:
    DOI:
    10.1021/ja01613a069
点击查看最新优质反应信息

文献信息

  • Compounds
    申请人:Hummersone Geoffrey Marc
    公开号:US20060199804A1
    公开(公告)日:2006-09-07
    Compounds of formula I: A-B-C  (I) and isomers, salts, solvates, chemically protected forms, and prodrugs thereof wherein: B is selected from the group consisting of: where R N is H or Me; or B is a divalent C 5 heterocyclic residue containing one or two ring heteroatoms; A is: R A3 and R A5 are independently selected from halo, OR O and R AC , where R O is H or Me, and R AC is H or C 1-4 alkyl; X A is selected from N and CR A4 , where R A4 is selected from H, OR O , CH 2 OH, CO 2 H, NHSO 2 Me and NHCOMe; R A2 and R A6 are independently selected from H, halo and OR O ; or R A3 and R A4 together with the carbon atoms to which they are attached, or RA2 and R A3 together with the carbon atoms to which they are attached, may form a C 5-6 heterocylic or heteroaromatic ring, containing at least one nitrogen ring atom; where if X is not N, 1, 2, or 3 of R A2 to R A6 are not H; C is: where X is selected from N and CH, Y is selected from N and CH, and Z is selected from N and CR C6 ; R C3 is selected from H, halo and an optionally substituted N-containing C 5-7 heterocyclic group; R C5 is a group selected from: which group may be selected by one or two C 1-4 alkyl groups or a carboxy group; R C6 is H; or, when X and Y are N, R C5 and R C6 (when Z is CR C6 ) together with the carbon atoms to which they are attached may form a fused C 6 aromatic ring selected from the group consisting of:
    化合物的化学式I: A-B-C  (I) 及其异构体、盐、溶剂合物、化学保护形式和前药,其中: B选自以下组合: 其中R N 为H或Me; 或B是含有一个或两个环异原子的二价C 5 杂环残基; A为: R A3 和R A5 独立选择自卤、OR O 和R AC ,其中R O 为H或Me,R AC 为H或C 1-4 烷基; X A 选自N和CR A4 ,其中R A4 选自H、OR O 、CH 2 OH、CO 2 H、NHSO 2 Me和NHCOMe; R A2 和R A6 独立选择自H、卤素和OR O ; 或R A3 和R A4 与它们连接的碳原子一起,或RA2和R A3 与它们连接的碳原子一起,可形成含有至少一个氮环原子的C 5-6 杂环或杂芳环; 如果X不是N,则R A2 至R A6 中的1、2或3个不是H; C为: 其中X选自N和CH,Y选自N和CH,Z选自N和CR C6 ; R C3 选自H、卤素和可选择性取代的含氮C 5-7 杂环基; R C5 为以下组合之一: 该组合可由一个或两个C 1-4 烷基或一个羧基选择; R C6 为H; 或者,当X和Y为N时,R C5 和R C6 (当Z为CR C6 时)与它们连接的碳原子可形成所选自的融合C 6 芳香环之一:
  • ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT
    申请人:Centre National de la Recherche Scientifique
    公开号:US20210009581A1
    公开(公告)日:2021-01-14
    The present invention concerns a compound of following general formula (I): where: either R is an R 1 group and R′ is an -A 1 -Cy 1 group, or R is an -A 1 -Cy 1 group and R′ is an R 1 group, R 1 particularly being H or (C 1 -C 6 )alkyl group; A 1 being an —NH— radical or —NH—CH 2 — radical; Cy 1 particularly being a phenyl group, A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.
    本发明涉及以下一般式(I)的化合物: 其中: R是R1基团且R′是-A1-Cy1基团,或者R是-A1-Cy1基团且R′是R1基团, 其中R1特别是H或(C1-C6)烷基基团; A1是—NH—基团或—NH—CH2—基团; Cy1特别是苯基, A是具有5到7个原子的融合(杂)芳香环, 用于治疗癌症。
  • Sulfur and selenium derivatives of quinazoline and pyrido[2,3-d]pyrimidine: Synthesis and study of their potential cytotoxic activity in vitro
    作者:Esther Moreno、Daniel Plano、Iranzu Lamberto、María Font、Ignacio Encío、Juan Antonio Palop、Carmen Sanmartín
    DOI:10.1016/j.ejmech.2011.10.056
    日期:2012.1
    The synthesis, cytotoxic activities and selectivities of 35 derivatives related to quinazoline and pyrido[2,3-d]pyrimidine are described. The synthesized compounds were screened in vitro against four tumoral cell lines – leukemia (CCRF-CEM), colon (HT-29), lung (HTB-54) and breast (MCF-7) – and two cell lines derived from non-malignant cell lines, one mammary (184B5) and one from bronchial epithelium
    描述了与喹唑啉和吡啶并[2,3- d ]嘧啶有关的35种衍生物的合成,细胞毒活性和选择性。体外针对四种肿瘤细胞系(白血病(CCRF-CEM),结肠(HT-29),肺(HTB-54)和乳腺癌(MCF-7))和两种源自非恶性肿瘤的细胞系筛选了合成的化合物细胞系,一种是乳腺(184B5),另一种是支气管上皮细胞(BEAS-2B)。MCF-7和HTB-54是最敏感的细胞系,其中11种和10种化合物的GI 50值分别低于10μM。鉴定出两种化合物(2o和3a)在所有测试的细胞系中均引起明显的细胞毒性作用,而一种化合物7h对MCF-7具有强效和选择性。对有效衍生物2o,3a和7h的机理的初步研究表明,这些化合物的细胞毒性活性可能是通过诱导细胞死亡而不影响细胞周期阶段来介导的。
  • A Green, Facile, and One-pot Synthesis of 2,4-(1<i>H</i>,3<i>H</i>)-Quinazolinediones under Microwave Irradiations
    作者:Farzad Nikpour、Touraj Paibast
    DOI:10.1246/cl.2005.1438
    日期:2005.10
    Quinazoline-2,4-diones are of considerable interest due to their wide pharmacological properties. Here, we have described an environmentally friendly method for the one-pot synthesis of 2,4-(1H,3H)-quinazolinediones from the reaction of anthranilic acid derivatives with urea in H 2 O media under microwave irradiations. This method is simple, safe, and fast which produces high yield of products without
    由于其广泛的药理特性,喹唑啉-2,4-二酮引起了相当大的兴趣。在这里,我们描述了一种环境友好的方法,用于从邻氨基苯甲酸衍生物与尿素在 H 2 O 介质中在微波辐射下的反应中一锅合成 2,4-(1H,3H)-喹唑啉二酮。该方法简单、安全、快速,无需任何催化剂,产品收率高。
  • MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH
    申请人:Tachdjian Catherine
    公开号:US20080306053A1
    公开(公告)日:2008-12-11
    The present invention provides screening methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors as well as modifiers capable of modulating chemosensory receptors and their ligands.
    本发明提供了用于识别化学感受受体及其配体的修饰因子的筛选方法,例如,通过确定测试实体是否适合与化学感受受体的捕蝇草结构域内的一个或多个相互作用位点发生相互作用,以及能够调节化学感受受体及其配体的修饰因子。
查看更多

同类化合物

阿昔替酯 螺喹唑啉 苯并[g][1,2,3]三唑并[4',5':5,6]吡啶并[2,1-b]喹唑啉-13(2H)-酮 脱氢利培酮 盐酸曲林菌素 甲硫利马唑 甲基8-乙基-2-甲氧基-5-氧代-5,8-二氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基8-乙基-2-(甲硫基)-5-氧代-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-羧酸酯 甲基2-乙氧基-8-乙基-5-氧代-吡啶并[6,5-d]嘧啶-6-羧酸酯 溴他替尼 泮托拉唑杂质DF 氨甲酸,[(2R,3E)-2-羟基-3-戊烯基]-,1,1-二甲基乙基酯(9CI) 柱孢藻毒素 曲美替尼 曲美替尼 曲喹辛 帕潘立酮棕榈酸酯 帕潘立酮杂质7 帕潘立酮杂质 帕潘立酮杂质 帕潘立酮 帕泊昔布杂质117 帕利哌酮十四酸酯 帕利哌酮N-氧化物 布喹特林 巴马斯汀 奥卡哌酮 多夸司特 吡曲克辛 吡嘧司特钾 吡嘧司特 吡啶并[4,3-d]嘧啶-4(1H)-酮,4,5,6,7-四氢-6-甲基-2-苯基- 吡啶并[4,3-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,4-D]嘧啶-2,4(1H,3H)-二酮 吡啶并[3,2-d]嘧啶-4(3H)-酮,3-甲基-2-(甲基氨基)- 吡啶并[3,2-d]嘧啶-4(3H)-酮 吡啶并[3,2-d]嘧啶-4(1H)-酮,2,3-二氢-3-(2-羟基苯基)-2-硫代- 吡啶并[3,2-d]嘧啶-2,4(1H,3H)-二酮 吡啶并[2,3-d]嘧啶-7(8h)-酮,2,6-二溴-8-环戊基-5-甲基- 吡啶并[2,3-d]嘧啶-7(8H)-酮 吡啶并[2,3-d]嘧啶-7(1H)-酮,4-氨基-5,6-二氢-5-甲基- 吡啶并[2,3-d]嘧啶-6-羧酸,1-(2,4-二甲基苯基)-1,4-二氢-2,7-二甲基-4-羰基-,酰肼 吡啶并[2,3-d]嘧啶-4(3H)-酮,5,7-二甲基-2-(甲硫基)-3-苯基- 吡啶并[2,3-d]嘧啶-4(3H)-酮 吡啶并[2,3-d]嘧啶-4(1H)-酮,2,3-二氢-1-(4-甲基苯基)-2-硫代- 吡啶并[2,3-d]嘧啶-2-胺 吡啶并[2,3-d]嘧啶 吡啶并[2,3-D]嘧啶-4-胺 吡啶并[2,3-D]嘧啶-2,4,7(1H,3H,8H)-三酮 吡啶并[2,3-D]嘧啶-2,4(1H,3H)-二酮